TNFSF13B and chronic graft versus host disease: In a clinical study on chronic graft-versus-host disease, 38 patients treated with MSCs showed a remarkable increase in the number of CD27+ and memory B cells, while plasma B-cell activating factor (BAFF) levels decreased and BAFF-R (BAFF receptor) expression increased on peripheral B cells (Peng et al., 2014).